Hep B Team


Viravaxx AG closely works with Prof. Rudolf Valenta, Medical University of Vienna. Prof. Valenta was instrumental in the basic research which led to Viravaxx’ VVX001 vaccine candidate. His outstanding scientific contribution enabled Viravaxx to initiate its ongoing hepatitis B clinical trial. 


Viravaxx AG is led by highly experienced executives with key competences in pharma and biotech.